Amicus Therapeutics to Announce Third Quarter 2016 Financial Results on November 7, 2016

CRANBURY, N.J., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Monday, November 7, 2016 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2016.

The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/, and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download, and install any necessary software.  

A telephonic replay of the call will be available for seven days beginning at 11:30 a.m. ET on November 7, 2016. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 10205490.

About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.

FOLD–G

CONTACTS:

Investors/Media:
Amicus Therapeutics
Sara Pellegrino
Senior Director, Investor Relations
[email protected]
(609) 662-5044

Media:
MWW PR
Sean Conley
[email protected]
(646) 381-9096

Source: Amicus Therapeutics, Inc

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• EQT Corp. (EQT) Tops Q1 EPS by 17c; offers outlook
• Renasant Corp. (RNST) Tops Q1 EPS by 3c